List of Excipients in Branded Drug SYNALAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medimetriks Pharmaceuticals Inc	SYNALAR	fluocinolone acetonide	43538-900	ANHYDROUS CITRIC ACID
Medimetriks Pharmaceuticals Inc	SYNALAR	fluocinolone acetonide	43538-900	BUTYLATED HYDROXYTOLUENE
Medimetriks Pharmaceuticals Inc	SYNALAR	fluocinolone acetonide	43538-900	CETYL ALCOHOL
Medimetriks Pharmaceuticals Inc	SYNALAR	fluocinolone acetonide	43538-900	DIMETHICONE 350
Medimetriks Pharmaceuticals Inc	SYNALAR	fluocinolone acetonide	43538-900	EDETATE DISODIUM

SYNALAR Excipient Strategy and Commercial Opportunities for Fluocinolone Acetonide Topical Products

Last updated: July 31, 2026

SYNALAR is a legacy topical corticosteroid brand based on fluocinolone acetonide, most commonly at 0.025% strength. Its commercial opportunity is no longer built on active-ingredient exclusivity. It is built on vehicle performance, tolerability, dosage-form differentiation, supply reliability, and regulatory execution.

The strongest opportunities are modernized creams, ointments, scalp solutions, emulsion vehicles, preservative-reduced products, pediatric-friendly formats, and contract-manufactured private-label products. The principal regulatory route is an abbreviated new drug application for products that match the reference product in active ingredient, strength, dosage form, route, and relevant formulation characteristics.

What is SYNALAR and which fluocinolone acetonide products are commercially relevant?

SYNALAR contains fluocinolone acetonide, a synthetic fluorinated corticosteroid used for corticosteroid-responsive dermatoses. The historical SYNALAR product family included topical cream, ointment, and solution presentations, generally at 0.025% fluocinolone acetonide concentration.

Attribute	SYNALAR commercial profile
Active ingredient	Fluocinolone acetonide
Common strength	0.025%
Drug class	Topical corticosteroid
Route	Topical dermatologic administration
Historical dosage forms	Cream, ointment, solution
Therapeutic use	Inflammatory and pruritic corticosteroid-responsive dermatoses
Current commercial position	Legacy brand with generic fluocinolone acetonide competition
Primary differentiation opportunity	Vehicle, tolerability, sensory profile, packaging, and distribution
Core regulatory pathway	ANDA for equivalent generic products; 505(b)(2) for materially differentiated products

Fluocinolone acetonide is also marketed in other topical products, including lower-strength preparations and specialty vehicles. Those products should not be treated as interchangeable commercial or regulatory references. A formulation strategy must account for strength, dosage form, vehicle composition, labeled population, and intended site of application.

When does SYNALAR lose exclusivity?

SYNALAR’s commercial exclusivity has expired. Fluocinolone acetonide is an established topical corticosteroid, and generic products have been marketed for years.

The relevant commercial question is therefore not whether a generic can enter after an expected patent expiry. It is whether a new product can obtain approval, demonstrate pharmaceutical and therapeutic equivalence where required, and compete against low-cost generic supply.

What is the Orange Book status of SYNALAR?

The FDA Orange Book is the principal source for patents and exclusivity associated with approved drug products. A legacy topical brand may have limited or no current Orange Book relevance where the branded product is discontinued, no longer the reference product, or lacks active listed exclusivity.

For a fluocinolone acetonide topical product, the decisive regulatory work is usually:

1. Identifying the FDA reference listed drug.
2. Confirming the exact strength and dosage form.
3. Reviewing the product-specific FDA product-specific guidance.
4. Assessing whether the proposed excipient composition supports ANDA equivalence.
5. Determining whether any listed patent requires a Paragraph IV certification.

A brand name alone does not establish a current enforceable patent barrier. Patent, exclusivity, and reference-product information must be checked in the FDA Orange Book and Drugs@FDA before filing or licensing decisions are made (U.S. Food and Drug Administration, n.d.-a, n.d.-b).

What patents protect SYNALAR and fluocinolone acetonide?

The basic active-ingredient protection for fluocinolone acetonide is expired. Commercial protection is more likely to arise from:

• Formulation patents covering a specific emulsion or oil vehicle.
• Delivery systems for scalp, pediatric, or occluded application.
• Preservative-free packaging.
• Combination products.
• New concentrations or dosing regimens.
• Manufacturing processes that improve particle size, uniformity, or stability.
• Method-of-use claims directed to a defined dermatologic condition or patient population.

The historic SYNALAR formulation itself is unlikely to provide a meaningful modern blocking position unless a live patent covers a specific formulation, use, or delivery configuration. A freedom-to-operate review should search patents assigned to the original brand owner, current generic manufacturers, specialty dermatology companies, and excipient or packaging suppliers.

How strong is the patent estate for a new SYNALAR formulation?

A conventional fluocinolone acetonide cream has weak standalone patentability. A patent application directed only to the active ingredient in a standard oil-in-water cream would face substantial prior-art risk.

Patent strength improves when the product claims include measurable technical features, such as:

• A defined droplet-size distribution.
• A specified active-particle size range.
• Improved stability under accelerated storage.
• Reduced skin irritation or sensitization.
• Enhanced deposition in the stratum corneum.
• Reduced systemic absorption.
• A preservative-free multidose package.
• A hydrogel or foam with a defined rheological profile.
• A vehicle that supports clinically meaningful treatment of the scalp or intertriginous areas.

A formulation patent should link the excipient selection to a technical result. Broad claims covering familiar dermatologic excipients are vulnerable to obviousness challenges.

Which excipients define the SYNALAR product opportunity?

The principal excipient strategy depends on the target dosage form.

Cream vehicle strategy

A fluocinolone acetonide cream typically uses an oil-in-water emulsion. The vehicle may include:

• Purified water.
• Mineral oil or another emollient oil.
• Fatty alcohols such as cetyl or stearyl alcohol.
• Stearic acid.
• Propylene glycol or another humectant and cosolvent.
• Petrolatum.
• Parabens or another preservative system.
• Emulsifiers and pH-adjusting agents.

A conventional cream offers the broadest commercial market because it is familiar, spreadable, and acceptable for many body sites. Its weaknesses are preservative sensitivity, phase stability, residue, and potential stinging from propylene glycol or alcohol-containing components.

Commercially differentiated cream concepts include:

Concept	Excipient objective	Commercial value
Low-residue cream	Reduce petrolatum and heavy oil content	Better adherence for daytime use
Barrier-support cream	Add compatible lipid or ceramide system	Premium dermatology positioning
Sensitive-skin cream	Remove fragrance and reduce irritant excipients	Pediatric and facial-use appeal
Preservative-reduced cream	Use package and water-activity controls	Lower sensitization concern
Fast-absorbing emulsion	Optimize droplet size and rheology	Improved patient preference
High-emolliency cream	Increase occlusive phase	Dry, lichenified, or cracked skin positioning

The commercial risk is that vehicle modifications may affect fluocinolone acetonide release, skin permeation, preservative performance, and bioequivalence. Every change must be evaluated against the intended regulatory pathway.

Ointment vehicle strategy

An ointment generally provides greater occlusion and emolliency than a cream. Petrolatum, mineral oil, polyethylene-based gelling agents, and related hydrocarbon excipients are common design options.

Ointments are attractive for dry, thickened, or highly scaly lesions. Their limitations are greasiness, clothing transfer, poor cosmetic acceptability, and lower preference for daytime use.

A premium ointment opportunity could focus on:

• Lower tack.
• Easier wash-off.
• Improved spreadability at room temperature.
• Reduced staining or transfer.
• Stable performance in cold-chain-free distribution.
• Unit-dose or metered packaging.

The formulation must preserve the pharmacologic effect of fluocinolone acetonide while improving the sensory profile. A lighter ointment may lose the occlusive performance that supports its therapeutic rationale.

Solution vehicle strategy

A solution is particularly relevant for the scalp and hair-bearing areas. It can improve application to areas where a cream or ointment is difficult to distribute.

Potential excipient systems include water, alcohol, propylene glycol, polyethylene glycol, and other cosolvents. The main formulation constraints are:

• Stinging on inflamed or excoriated skin.
• Flammability where alcohol is used.
• Hair greasiness.
• Drying or irritation from volatile solvents.
• Packaging compatibility.
• Evaporation-related concentration changes.
• Patient concerns about odor.

A modern scalp solution could differentiate through reduced alcohol content, lower odor, non-greasy drying, or a metered applicator. The package should control dose delivery and reduce hand contact.

Gel, foam, and spray opportunities

Gel, foam, and spray dosage forms could create stronger differentiation than another conventional cream. These formats may improve scalp application, reduce residue, or provide a more modern user experience.

They also create greater regulatory and technical risk. The sponsor must evaluate:

• Droplet or foam structure.
• Dose uniformity.
• Propellant selection, if applicable.
• Container-closure compatibility.
• Flammability.
• In-use stability.
• Delivery to hair-bearing skin.
• Local tolerability.
• In vitro release and permeation.

A foam or spray may support a 505(b)(2) strategy if the product differs materially from the reference product and requires reliance on existing clinical or safety information. The commercial case must justify the higher development and manufacturing cost.

What excipients create the strongest commercial opportunities?

The most attractive excipient opportunities combine patient preference with a measurable technical advantage.

Preservative strategy

Preservatives can create regulatory and commercial problems in topical dermatology. Parabens, phenoxyethanol, benzyl alcohol, and other systems may cause concern among patients or clinicians, even when supported by established safety data.

A preservative-reduced or preservative-free product can command a premium if it has:

• A suitable low-water or anhydrous vehicle.
• A validated multidose package.
• Low water activity.
• Microbiological integrity through the labeled shelf life.
• Acceptable in-use stability.

Airless pumps, unit-dose sachets, laminated tubes, and valve systems can support this strategy. Packaging is part of the formulation design because it affects microbial protection, dose delivery, stability, and cost.

Humectants and cosolvents

Propylene glycol can improve solubilization, hydration, and skin penetration, but it may sting or irritate compromised skin. Substitution with glycerin, polyethylene glycol, pentylene glycol, or other multifunctional excipients may improve tolerability but can alter viscosity, drug release, and preservative performance.

A successful substitution requires comparative testing for:

• Fluocinolone acetonide assay.
• Related substances.
• Viscosity.
• pH.
• Particle or droplet distribution.
• In vitro release.
• Skin permeation.
• Microbial limits.
• Freeze-thaw and accelerated stability.

Lipid and barrier-support systems

Ceramides, cholesterol, fatty acids, and structured lipid systems can support a barrier-repair positioning. The technical challenge is preventing the lipid system from changing corticosteroid release or causing phase instability.

These excipients may support a differentiated product for eczema-prone or very dry skin, but the sponsor should avoid implying treatment claims beyond the approved corticosteroid indication unless supported by clinical evidence and permitted labeling.

Rheology modifiers

Carbomers, cellulose derivatives, acrylate polymers, clays, and related thickeners can control spreadability, residence time, and drip resistance. Rheology is commercially important for scalp solutions, gels, and lotions.

The key parameters are:

• Yield stress.
• Shear-thinning behavior.
• Spread diameter.
• Extrusion force.
• Residual film.
• Wash-off profile.
• Temperature sensitivity.

A product that spreads easily under finger pressure but remains localized after application can improve adherence without relying on a heavy occlusive base.

What regulatory pathway applies to a new SYNALAR excipient formulation?

ANDA pathway

An ANDA is the most direct route for a product that matches the reference product in active ingredient, strength, dosage form, route, and relevant performance characteristics. The formulation may contain different inactive ingredients when the FDA determines that the differences do not affect safety or efficacy and the product meets applicable equivalence requirements.

For topical products, development normally includes:

• Pharmaceutical equivalence.
• Comparative composition assessment.
• In vitro release testing.
• In vitro permeation testing where relevant.
• Product quality and stability data.
• Local irritation or sensitization assessment when required.
• Comparative clinical endpoint or other FDA-specified evidence.

FDA’s topical dermatologic guidance places significant weight on product quality and performance rather than relying only on conventional pharmacokinetic measurements (U.S. Food and Drug Administration, 2022).

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a novel dosage form, new route-related presentation, new concentration, or materially different delivery system. Examples could include:

• A fluocinolone acetonide foam.
• A metered scalp spray.
• A specialized low-irritancy vehicle.
• A new combination involving a barrier-support or antimicrobial component.
• A product with a new dosing regimen.

The pathway may support three-year marketing exclusivity for certain new clinical investigations, but it does not restore broad active-ingredient exclusivity. The value depends on whether the product has a clinically credible advantage and sufficient market access.

What generic entry risks exist for SYNALAR?

Generic entry risk is high for conventional cream and ointment products. Several factors reduce barriers:

• Expired active-ingredient protection.
• Familiar excipient technology.
• Established manufacturing processes.
• Multiple potential suppliers.
• Low clinical complexity.
• Broad availability of dermatology contract manufacturers.

The primary barriers are formulation reproducibility, topical equivalence, raw-material variability, and manufacturing scale. A product may be legally simple but technically difficult to reproduce if its performance depends on tightly controlled emulsification, particle size, or packaging.

Which companies are challenging SYNALAR?

The competitive field consists mainly of generic manufacturers and dermatology-focused suppliers rather than companies pursuing a direct branded patent challenge. Manufacturers active in topical corticosteroids include large generic companies such as Perrigo, Taro, Fougera, Glenmark, Teva, and related authorized or contract manufacturers, depending on product strength and dosage form.

Competitive diligence should compare:

• Approved dosage forms.
• Strengths.
• National Drug Code status.
• Current availability.
• Wholesale acquisition cost.
• Pharmacy substitution.
• Tube sizes.
• Private-label supply.
• Back-order history.
• FDA inspection and warning-letter history.

Market participation can change quickly because topical generics are often supplied through contract manufacturing and private-label arrangements.

How does SYNALAR compare with competing topical corticosteroids?

Fluocinolone acetonide competes with hydrocortisone, desonide, triamcinolone acetonide, betamethasone valerate, fluocinonide, and other topical corticosteroids. The competitive position depends on potency, body site, duration of use, dosage form, and prescriber preference.

Product class	Commercial positioning	Excipient opportunity
Hydrocortisone	Lower-potency, broad OTC and prescription use	Cosmetic acceptability and sensitive-skin formats
Desonide	Low-potency prescription dermatology	Premium pediatric and facial-use vehicles
Fluocinolone acetonide	Low-to-mid potency depending on formulation and labeling	Vehicle modernization and scalp delivery
Triamcinolone acetonide	Broadly used mid-potency steroid	Low-cost generic scale and multiple dosage forms
Fluocinonide	Higher-potency prescription steroid	High-adherence vehicles with controlled application
Betamethasone products	Potency and formulation-specific competition	Foam, lotion, and scalp formats

SYNALAR’s opportunity is strongest where the vehicle solves an application problem. A new product is less likely to win solely through a lower price because established generic creams and ointments are difficult to undercut sustainably.

What manufacturing and intellectual-property barriers affect commercialization?

Manufacturing barriers are more important than active-ingredient patent barriers.

Critical process controls include:

• Homogeneous distribution of low-dose fluocinolone acetonide.
• Control of active particle size.
• Emulsion droplet-size distribution.
• Temperature and shear during homogenization.
• Cooling profile.
• Deaeration.
• Tube filling accuracy.
• Preservative dispersion.
• Container-closure compatibility.
• Microbial control.

For semisolid products, changes in mixing energy, batch scale, raw-material grade, or cooling rate can affect drug release. A robust control strategy should link critical material attributes and critical process parameters to finished-product performance.

IP barriers may arise from:

• Proprietary airless packaging.
• Licensed foam technology.
• Specialty emulsifiers.
• Novel lipid systems.
• Metered-dose applicators.
• Manufacturing know-how.
• Exclusive distribution agreements.

Trade secrets can be commercially important even where patents are weak. A formulation with difficult-to-reproduce rheology or release performance may create a practical barrier against rapid copy products.

What licensing deals could create value?

The most realistic licensing targets are platform technologies rather than SYNALAR-specific rights. Potential deal structures include:

1. Vehicle license: Rights to a dermatology emulsion, foam, gel, or spray platform.
2. Packaging license: Airless, unit-dose, or metered topical delivery system.
3. Contract manufacturing agreement: Supply of a validated fluocinolone acetonide product.
4. Private-label agreement: Retail, teledermatology, or specialty-pharmacy distribution.
5. Regional commercialization license: Rights limited to the United States, Europe, or selected emerging markets.
6. Combination-product license: Fluocinolone acetonide with barrier-support or antimicrobial positioning.

A license is most defensible when it includes formulation know-how, analytical methods, scale-up support, and regulatory documentation. A patent-only license has less value for a conventional topical corticosteroid unless the claims cover a commercially important dosage form.

What revenue exposure and launch scenarios are realistic?

A conventional generic SYNALAR product is exposed to rapid price erosion and pharmacy substitution. A differentiated product can reduce this exposure through specialty distribution, branded copay support, dermatology sales, or a clinically supported vehicle claim.

Launch scenario	Product profile	Expected commercial position
Low-cost generic	Conventional cream or ointment	High substitution, low margin
Retail private label	Standardized generic vehicle	Volume-driven, limited differentiation
Premium dermatology generic	Low-irritancy or preservative-reduced cream	Moderate price premium
Scalp-focused product	Solution, gel, foam, or spray	Differentiated prescribing opportunity
Specialty branded product	Novel vehicle and packaging	Higher margin, greater development cost
Pediatric-focused product	Gentle excipient system and convenient package	Higher adherence value, evidence burden

Revenue depends on more than prescription volume. Formulation, package size, channel mix, reimbursement, generic substitution, and manufacturing cost determine net sales.

Key Takeaways

• SYNALAR is a legacy fluocinolone acetonide brand with no meaningful remaining active-ingredient exclusivity.
• Conventional cream and ointment products face high generic competition and limited patent protection.
• The strongest commercial opportunities are vehicle modernization, scalp delivery, preservative-reduced systems, barrier-support formulations, and improved packaging.
• An ANDA is the primary route for equivalent generic products.
• A 505(b)(2) application may support materially differentiated dosage forms such as foams, sprays, or novel delivery systems.
• Formulation performance, scale-up, microbial control, and topical equivalence are the main technical barriers.
• A valuable license would include formulation know-how, analytical methods, manufacturing support, and packaging rights.
• A premium product needs a measurable benefit in tolerability, application, adherence, or delivery to avoid competing solely on price.

FAQs

Can fluocinolone acetonide be reformulated without obtaining new clinical trials?

Often, an equivalent topical product can pursue an ANDA with formulation and performance data rather than a full independent clinical program. The required evidence depends on the reference product, dosage form, excipient differences, and FDA product-specific guidance.

Is a preservative-free SYNALAR cream commercially viable?

Yes, if the product uses a suitable package and has validated microbiological protection, stability, and in-use performance. A preservative-free claim alone is unlikely to support a durable premium without improved tolerability or packaging convenience.

Does a new fluocinolone acetonide vehicle qualify for three-year FDA exclusivity?

A 505(b)(2) product may qualify for three-year exclusivity if approval relies on new clinical investigations essential to approval. A simple formulation change without qualifying clinical evidence generally does not create the same exclusivity position.

Can a scalp foam command a higher price than SYNALAR cream?

It can, if the foam improves application to hair-bearing skin, reduces residue, and supports adherence. The premium depends on clinical differentiation, payer coverage, manufacturing cost, and competition from other topical corticosteroid foams.

Are excipients patentable in a fluocinolone acetonide product?

Individual conventional excipients are rarely sufficient for strong protection. Patent value is greater when the excipient system is tied to a novel composition, defined physical properties, improved stability, altered skin deposition, reduced irritation, or a specialized delivery device.

References

1. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

4. U.S. Food and Drug Administration. (n.d.-c). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

5. U.S. National Library of Medicine. (n.d.). DailyMed: Fluocinolone acetonide topical products. https://dailymed.nlm.nih.gov/dailymed/